Retatrutide

The Triple GLP-1/GIP/Glucagon Agonist Peptide is a synthetic peptide designed to simultaneously activate the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This triple receptor targeting allows comprehensive modulation of metabolic pathways involved in appetite control, fat metabolism, glucose regulation, and energy balance.

Pharmacokinetics and mechanism highlights include:

• The peptide adopts a continuous helical structure facilitating robust receptor binding and activation across all three targets.
• It shows highest potency at the GIP receptor, balanced activity at GLP-1 receptor, and lower potency at the glucagon receptor, enabling a tailored metabolic effect profile.
• Acylation with a fatty diacid moiety prolongs the half-life to approximately six days, supporting convenient once-weekly dosing.
• Metabolism is primarily hepatic and does not involve cytochrome P450 enzymes, minimizing drug-drug interaction potential.
• Clinically, this peptide produces substantial weight loss, improved glycemic control (HbA1c reduction), and favorable effects on lipid profiles and blood pressure.
• Common adverse effects include gastrointestinal symptoms such as nausea, diarrhea, vomiting, and constipation, often dose-dependent.

The Triple GLP-1/GIP/Glucagon Agonist Peptide is supplied exclusively as a research-grade peptide for laboratory investigation. It is not intended for diagnostic, therapeutic, or clinical use without regulatory approval. For Research Use Only.

Product details:

• Molecular Structure: Single continuous helical peptide with N-terminal segment targeting transmembrane receptor cores and C-terminal interactions with extracellular domains
• Molecular modifications: Fatty diacid acylation for increased half-life
• Half-life: Approximately 6 days (supports once-weekly administration)
• Appearance: White to off-white lyophilized powder

This product is intended exclusively for scientific research and laboratory investigation in compliance with applicable regulatory guidelines.